Is Basilea likely to get a buyout offer?

Shares of Basilea Pharmaceutica shot up as speculation about a possible takeover attempts heats up. Basilea recently won a $130 million arbitration award from J&J, which was held responsible for botching clinical trial work on ceftobiprole. The anti-infective was shot down by regulators in Europe and the U.S. after they determined that the data presented was unreliable. Now the biotech's low market value, pipeline of new anti-infectives and cash in the bank has made it an attractive takeover target, according to some analysts. Story

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.